Method for determining mutateable ligand-gpcr binding at single amino acid resolution and pairs of mutated ligand and gpcr

Abstract

Method of determining GPCR and mutateable ligand binding ability, includes providing a well microtiter plate with well array having rows and columns, GPCR or rhodopsin in wells, and parent ligand mutant binding to GPCR when GPCR resides in conformation, contacting parent ligand mutants in wells with GPCR, coupling parent ligand to GPCR, and determining mutant ligand binding strength compared to standard parent ligand and GPCR by determining coupled mutant-GPCR complex in wells. Rhodopsin binding 403 mutants covering arrestin sequence provides functional 4th dimension arrestin crystal structures. Resulting single amino acid resolution functional maps reveal critical interactions in arrestin polar core and C-tail interrupted during activation. Amino acid patches reduce binding and act as direct binding rhodopsin interfaces. This and computational molecular docking active arrestin4 and light-activated rhodopsin develop arrestin-rhodopsin complex model. Combined mutants allow binding affinity modification and GPCR-ligand complex stability for diagnostics or intervention.